Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026
Exelixis, a biotech company, has shown strong financial performance over the past five years, largely due to its successful cancer drug, Cabometyx. While Cabometyx faces potential generic competition by early 2030, Exelixis is developing a new cancer medicine, zanzalintinib, and has other pipeline candidates to mitigate this risk. The company's strategic development and strong market position make it a compelling investment consideration.
Exelixis director Wyszomierski sells $4.38 million in stock
Exelixis director Jack L. Wyszomierski sold 99,574 shares of common stock for approximately $4.38 million on February 18, 2026, under a Rule 10b5-1 trading plan. On the same day, Wyszomierski also exercised options to acquire 20,634 shares. The company recently reported a Q4 2025 EPS beat, although revenue missed expectations, leading H.C. Wainwright to raise its price target to $54 and Citizens to reaffirm its Market Outperform rating with a $50 price target.
Exelixis director Smith sells $4.68m in stock after option exercise
Exelixis director Julie Smith sold approximately $4.68 million worth of company stock on February 17 and 18, 2026, after exercising options to acquire the shares. These transactions involved 106,539 shares overall, with sales prices ranging from $43.33 to $44.50 and option exercise prices between $18.19 and $21.69. Following the sales, Smith directly owns 20,590 Exelixis shares.
Exelixis director Smith sells $4.68m in stock after option exercise
Julie Smith, a director at Exelixis, Inc., recently sold approximately $4.68 million worth of common stock after exercising options. The transactions involved 106,539 shares sold across February 17 and 18, 2026, at prices between $43.33 and $44.50. This comes as Exelixis shows strong stock momentum, gaining 26% over the past year, while recent company news includes exceeding EPS forecasts for Q4 2025 and positive analyst ratings for its cancer treatment zanzalintinib.
Exelixis director Oliver Bob sells $1.3m in stock
Exelixis director Oliver Bob sold 30,250 shares of common stock for approximately $1.3 million on February 13, 2026, and also exercised options to acquire 9,088 shares. Despite these sales, the company maintains an excellent financial health score and recently surpassed its fourth-quarter 2025 EPS estimates. Analysts have reiterated positive ratings and price targets, bolstered by insights into their cancer drug zanzalintinib.
Exelixis Inc. (NASDAQ:EXEL) Stands Out as a Quality Investing Candidate
Exelixis Inc. (NASDAQ:EXEL) has been identified as a strong candidate for quality investing, highlighted by its performance on the "Caviar Cruise" stock screen. The biopharmaceutical company demonstrates robust financial health with high profitability, strong earnings growth, excellent capital utilization, and a solid financial condition characterized by no net debt and superior cash conversion. These factors, alongside a high fundamental score, position Exelixis as a compelling long-term investment in the oncology sector.
Exelixis EVP Haley sells $2.95 million in stock
Exelixis (NASDAQ:EXEL) Executive Vice President, Commercial, Patrick J. Haley, recently sold 67,814 shares of company stock for approximately $2.95 million. Despite the sale, InvestingPro analysis suggests the company is undervalued with a low P/E ratio relative to near-term earnings growth. Exelixis has an "EXCELLENT" financial health score and analysts have price targets ranging from $35 to $60.
Exelixis SVP Hefti sells $821k in stock
Exelixis Senior Vice President Brenda Hefti sold over $821,000 worth of company stock on February 18, 2026, and an additional $238,000 to cover tax obligations. These sales were conducted under a pre-arranged 10b5-1 trading plan. Despite the insider selling, InvestingPro data indicates aggressive share buybacks by management, and analysts hold a positive outlook on Exelixis, raising price targets after a strong Q4 2025 earnings beat and promising drug data.
Exelixis EVP and CFO Senner sells $2.8 million in stock
Exelixis (NASDAQ:EXEL) EVP and CFO Christopher J. Senner sold approximately $2.8 million worth of common stock between February 13 and February 17. Despite these sales, InvestingPro analysis suggests the biopharmaceutical company may be undervalued, with an 8% free cash flow yield and aggressive share buybacks by management. The company also recently reported strong Q4 2025 earnings per share, although revenues slightly missed expectations, leading to adjusted price targets from analysts.
Exelixis Director Oliver Bob Sells Shares
Exelixis Director Oliver Bob sold 30,250 shares of the company's common stock for over $1.3 million on February 13, 2026. The sales were conducted in two transactions at prices of $43.61 and a weighted average of $43.9 per share. Following these transactions, Bob still directly owns 21,120 shares, including future vested RSUs.
Rhumbline Advisers Decreases Holdings in Exelixis, Inc. $EXEL
Rhumbline Advisers significantly reduced its stake in Exelixis, selling 27,580 shares in Q3, now holding 749,216 shares valued at $30.94 million. Insiders also sold 72,230 shares, with EVP Patrick J. Haley selling 34,187 shares for over $1.4 million. Despite these sales, Exelixis reported strong Q3 earnings, beating EPS estimates and achieving $598.7 million in revenue, while maintaining a "Hold" consensus rating from analysts with a target price of $47.11.
Assetmark Inc. Has $131.99 Million Stock Position in Exelixis, Inc. $EXEL
Assetmark Inc. significantly increased its stake in Exelixis, Inc. ($EXEL) by over 1,200% in Q3, now holding 3.19 million shares valued at $131.99 million. The biotechnology company recently beat Q4 EPS expectations but missed on revenue, while preparing for a potential 2026 launch of its colorectal cancer drug, zanzalintinib. Analyst sentiment is mixed, with an average price target of $47.11, reflecting both confidence in the pipeline and near-term uncertainties from conservative revenue guidance.
Exelixis stock price target raised to $54 from $52 at H.C. Wainwright
H.C. Wainwright increased its price target for Exelixis (NASDAQ:EXEL) to $54 from $52, maintaining a Buy rating after the biopharmaceutical company reported better-than-expected Q4 2025 diluted net income of $0.88 per share. This positive adjustment is supported by InvestingPro data indicating the stock is trading below its Fair Value with a low PEG ratio. The firm also projected an increase in full-year 2026 net earnings to $3.15 per share, citing the company's strong cash position.
Exelixis, Inc. $EXEL Shares Sold by LSV Asset Management
LSV Asset Management reduced its stake in Exelixis, Inc. by 0.7% in the third quarter, holding 7,768,627 shares worth $320,844,000. Other hedge funds also made minor adjustments to their holdings. Exelixis reported strong quarterly earnings, beating analyst estimates, and analysts have mixed ratings on the stock with a consensus "Hold" and a target price of $47.11.
Exelixis stock price target raised to $54 from $52 at H.C. Wainwright
H.C. Wainwright has increased its price target for Exelixis (NASDAQ:EXEL) to $54 from $52, maintaining a Buy rating, following the biopharmaceutical company's strong fourth-quarter 2025 earnings. Exelixis reported diluted net income of $0.88 per share, surpassing forecasts, and generated $598.7 million in total revenue. The firm also adjusted its full-year 2026 net earnings projection for Exelixis upwards and noted the company's substantial cash reserves.
Exelixis Reports Solid Earnings-Are New Highs Back on the Table?
Exelixis reported solid, albeit mixed, fourth-quarter earnings, with EPS significantly exceeding estimates but revenue falling slightly short. The company's franchise strategy, focused on building comprehensive treatment ecosystems around specific drug molecules like Cabometyx and the pipeline candidate zanzalintinib, positions it for future growth, particularly with a potential $5 billion peak sales opportunity for zanzalintinib. Despite trading at a slight premium, analysts have raised price targets, anticipating new highs within the next 12 months if growth materializes and the company's transition to a multi-franchise oncology player proves successful.
Exelixis outlines growth strategy as CABOMETYX franchise hits $2.12B, eyes 2026 zanzalintinib launch
Exelixis detailed its growth strategy, highlighted by the strong performance of its CABOMETYX franchise, which generated $2.12 billion in revenue. The company is actively preparing for the potential launch of zanzalintinib in 2026, a key component of its future pipeline. This strategy focuses on leveraging existing successes while expanding into new therapeutic areas with novel compounds.
Exelixis, Inc. (NASDAQ:EXEL) Q4 2025 Earnings Call Transcript
Exelixis, Inc. reported strong Q4 and full-year 2025 financial results, with US cabozantinib franchise net product revenues growing 17% to $2.12 billion for the full year. The company is advancing zanzalintinib as its next oncology franchise, with an NDA accepted for the ZanzaAteza combination in third-line plus colorectal cancer and seven ongoing pivotal trials. Exelixis aims to build a multi-franchise business in solid tumor oncology, focusing on expanding its leadership in GI indications while continuing to grow its cabozantinib business in GU oncology.
Essex Investment Management Co. LLC Raises Stock Position in Exelixis, Inc. $EXEL
Essex Investment Management Co. LLC significantly increased its stake in Exelixis, Inc. by 3,670.7% in Q3, acquiring 44,415 additional shares. This move is part of a broader trend where several institutional investors, including Norges Bank and Qube Research & Technologies Ltd, built substantial positions in the biotechnology company. Despite a Q4 EPS beat, Exelixis missed revenue estimates, and analysts maintain a "Hold" consensus on the stock.
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
Exelixis reported strong financial results for the fourth quarter and fiscal year 2025, with total revenues reaching $2.320 billion for the fiscal year. The company's cabozantinib franchise showed significant growth, and Exelixis is positioning for further expansion with its zanzalintinib program, including a recently accepted New Drug Application by the FDA. Exelixis anticipates a milestone-rich year in 2026 with key clinical trial readouts and initiations, while also maintaining its financial guidance and continuing its stock repurchase program.
Exelixis Inc (NASDAQ:EXEL) Reports Mixed Q4 2025 Results, Beats on EPS but Misses on Revenue
Exelixis Inc (NASDAQ:EXEL) announced mixed financial results for Q4 2025, surpassing EPS estimates with $0.94 per share but falling short on revenue with $598.7 million against a $616.2 million forecast. Despite initial after-hours stock decline, the company maintained its 2026 financial guidance, which is conservative as it excludes potential contributions from its new drug zanzalintinib, currently awaiting FDA approval. While the cabozantinib franchise continues strong, the focus is now on the successful launch of zanzalintinib and diversification of its revenue streams.
Why Exelixis (EXEL) is one of the best healthcare stocks under $50 to invest in
This article identifies Exelixis (EXEL) as a top healthcare stock under $50, suggesting it presents a compelling investment opportunity. The selection likely stems from its financial performance, growth prospects, or market position within the healthcare sector. Investors looking for affordable yet promising healthcare options may find EXEL to be a strong candidate.
(EXEL) Exelixis Expects Full Year 2026 Revenue Range $2.53B - $2.63B, vs. FactSet Est of $2.62B
Exelixis (EXEL) expects its full-year 2026 revenue to be in the range of $2.53 billion to $2.63 billion, which is closely aligned with FactSet's estimated $2.62 billion. This forecast puts the company's anticipated revenue slightly above the consensus. The oncology company recently announced that the U.S. FDA accepted the New Drug Application for Zanzalintinib in combination with an immune checkpoint inhibitor for metastatic colorectal cancer.
EXELIXIS, INC. SEC 10-K Report
Exelixis, Inc. released its 2025 Form 10-K report, detailing robust financial performance with significant increases in total revenues, net income, and EPS, driven by strong CABOMETYX sales. The report also highlighted key business milestones, including product portfolio expansion, advancements in pipeline programs like zanzalintinib, and strategic collaborations. The company outlined future strategic initiatives such as pipeline expansion through internal research and external collaborations, active capital management via share repurchases, and addressed challenges like commercialization, regulatory, and operational risks in the competitive biopharmaceutical industry.
Exelixis: Q4 Earnings Snapshot
Exelixis Inc. (EXEL) reported strong fourth-quarter earnings, with net income reaching $244.5 million, or 88 cents per share, surpassing Wall Street expectations. The company's revenue also exceeded forecasts, coming in at $598.7 million for the quarter. For the full year, Exelixis reported a profit of $782.6 million on revenue of $2.32 billion, and anticipates full-year revenue for the upcoming year to be between $2.53 billion and $2.63 billion.
Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update
Exelixis reported strong financial results for the fourth quarter and fiscal year 2025, with total revenues of $599 million and $2.320 billion, respectively, driven by robust performance of its cabozantinib franchise. The company also announced key strategic updates, including the FDA's acceptance of an NDA for zanzalintinib in combination with atezolizumab for metastatic colorectal cancer and outlined significant clinical development milestones for 2026, positioning itself for continued growth and expansion of its oncology portfolio.
Exelixis earnings on deck: Can zanzalintinib justify valuation?
Exelixis Inc. is reporting fourth-quarter results, with investors keenly watching to see if its pipeline, particularly zanzalintinib, can justify current valuations and offset the eventual loss of exclusivity for its flagship drug, Cabometyx. Analysts are looking for updates on zanzalintinib's commercialization timelines and peak sales expectations, as well as confirmation of revenue growth from Cabometyx's expanded label in neuroendocrine tumors. The market is mixed on Exelixis, with some analysts expressing valuation concerns despite recent strong performance.
Exelixis: Q4 Earnings Snapshot
Exelixis Inc. (EXEL) reported strong fourth-quarter earnings, with net income reaching $244.5 million, or 88 cents per share, significantly surpassing Wall Street's expectations. Adjusted earnings per share were 94 cents, beating the average analyst estimate of 77 cents. The drug developer also exceeded revenue forecasts, posting $598.7 million in the quarter and projecting full-year revenue between $2.53 billion and $2.63 billion.
Why Exelixis (EXEL) is One of the Best Healthcare Stocks Under $50 to Invest In
Exelixis, Inc. (NASDAQ: EXEL) is highlighted as a top healthcare stock under $50, with Barclays recently raising its price target to $44. The company announced the acceptance of its New Drug Application (NDA) for zanzalintinib in combination with atezolizumab to treat metastatic colorectal cancer, targeting a December 3, 2026, FDA action date. While acknowledging EXEL's growth potential, the article suggests that certain AI stocks may offer higher returns and lower risk.
Morgan Stanley Maintains a Buy on Exelixis (EXEL) With a $48 PT
Morgan Stanley has reiterated its Buy rating on Exelixis (EXEL) with a price target of $48. This decision reflects the firm's continued positive outlook on the biopharmaceutical company's financial prospects and market position.
EXELIXIS INC (NASDAQ:EXEL) Combines Strong Growth Fundamentals with Bullish Technical Setup
EXELIXIS INC (NASDAQ:EXEL) demonstrates a compelling case for investment by combining strong growth fundamentals with a bullish technical setup. The company shows high profitability, sound financial health with no debt, and a firm growth trajectory, making it attractive for growth investors. Technically, EXEL is consolidating within a range, nearing a resistance level, which could signal a new upward trend upon a breakout.
Exelixis (EXEL) Is Up 6.1% After FDA Accepts Colorectal Cancer Combo NDA - What's Changed
Exelixis (EXEL) saw its stock rise by 6.1% after the FDA accepted its New Drug Application for zanzalintinib plus atezolizumab to treat metastatic colorectal cancer, with a target action date of December 3, 2026. This development strengthens Exelixis's oncology investment narrative by diversifying its solid-tumor portfolio beyond cabozantinib, though near-term revenue still relies heavily on CABOMETYX. The company's shares are considered potentially undervalued, and the FDA review adds key catalysts to its growth outlook.
FDA NDA Move Puts Exelixis Colorectal Cancer Bet To The Test
The FDA has accepted Exelixis' New Drug Application for zanzalintinib plus atezolizumab for metastatic colorectal cancer, with a PDUFA action date of December 3, 2026. This development is a crucial test for Exelixis' strategy to diversify its oncology pipeline beyond cabozantinib and positions the company against existing treatments. While it presents a potential new revenue stream, investors should monitor the final overall survival analysis in the non-liver metastases subgroup and regulatory updates for remaining uncertainties.
Assessing Exelixis (EXEL) Valuation After FDA Accepts Zanzalintinib NDA In Metastatic Colorectal Cancer
Exelixis (EXEL) has garnered attention after the FDA accepted its New Drug Application for zanzalintinib plus atezolizumab in metastatic colorectal cancer. Despite recent slight negative share price returns over one month and year-to-date, the company shows strong long-term performance with a 28.59% one-year total shareholder return. Analysts view EXEL as 6.6% undervalued, with a fair value of $45.61, highlighting its substantial free cash flow, strong balance sheet, and strategic R&D investments.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
Exelixis (EXEL) is identified as a strong momentum stock based on Zacks' proprietary rating system. The article details how Zacks Style Scores, particularly the Momentum Score, combined with the Zacks Rank, help investors identify stocks with high potential to outperform the market. EXEL holds a Zacks Rank #2 (Buy) and a VGM Score of A, with a Momentum Style Score of B, making it an attractive pick for investors.
Exelixis (EXEL) Reports Next Week: Wall Street Expects Earnings Growth
Exelixis (EXEL) is projected to report a significant year-over-year increase in earnings and higher revenues for the quarter ended December 2025. While the company has a strong Zacks Rank of #2, its Earnings ESP of -0.07% suggests that analysts have recently become more bearish, making an earnings beat difficult to predict conclusively. Investors are advised to consider other factors alongside the Earnings ESP and Zacks Rank when evaluating the stock.
FDA accepts Exelixis’ NDA for zanzalintinib in colorectal cancer By Investing.com
The FDA has accepted Exelixis’ New Drug Application for zanzalintinib in combination with atezolizumab to treat previously treated metastatic colorectal cancer. This application is supported by positive results from the phase 3 STELLAR-303 trial, which showed a significant improvement in overall survival. The FDA has set a target action date of December 3, 2026, for the standard review.
Colorectal cancer drug combo that cut death risk now under FDA review
Exelixis announced that its New Drug Application (NDA) for zanzalintinib in combination with atezolizumab has been accepted for U.S. FDA review for metastatic colorectal cancer. The FDA assigned a target action date of December 3, 2026. This application is based on positive results from the phase 3 STELLAR-303 trial, which showed the drug combination improved overall survival and reduced the risk of death in previously treated patients.
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Exelixis announced that the U.S. FDA has accepted its New Drug Application for zanzalintinib in combination with atezolizumab for previously treated metastatic colorectal cancer, assigning a target action date of December 3, 2026. The application is supported by results from the phase 3 STELLAR-303 trial, which showed improved overall survival and reduced risk of death compared to regorafenib. This combination offers a novel mechanism of action for patients with limited effective therapies.
The Technical Signals Behind (EXEL) That Institutions Follow
This article analyzes Exelixis Inc. (NASDAQ: EXEL) based on AI-generated technical signals, noting a weak near and mid-term sentiment despite a positive long-term outlook. It details specific institutional trading strategies including long, breakout, and short positions, and provides multi-timeframe signal analysis with support and resistance levels. The report highlights a significant risk-reward short setup for EXEL.
Exelixis Announces U.S. FDA Accepted the New Drug Application for Zanzalintinib in Combination with an Immune Checkpoint Inhibitor for Patients with Metastatic Colorectal Cancer
Exelixis announced that the U.S. FDA has accepted its New Drug Application (NDA) for zanzalintinib in combination with atezolizumab for treating metastatic colorectal cancer patients. The FDA assigned a Prescription Drug User Fee Act target action date of December 3, 2026. This application is based on positive results from the phase 3 STELLAR-303 trial, which showed improved overall survival compared to regorafenib.
Assessing Exelixis (EXEL) Valuation After Recent Share Price Volatility
Exelixis (EXEL) has experienced recent stock volatility but shows strong long-term momentum, with a 1-year return of 24.77% and a 3-year return of 135.67%. Despite short-term declines, the company's valuation, at $41.36 against a narrative fair value of $45.61, suggests it is undervalued. This is supported by its substantial free cash flow, strong balance sheet, and disciplined capital allocation.
Is Exelixis (EXEL) Using Zanzalintinib To Quietly Redefine Its Post-Cabometyx Strategy?
Exelixis recently submitted an FDA application for zanzalintinib, a next-generation cancer drug, to be used in combination with Tecentriq for metastatic colorectal cancer. This move is strategic for Exelixis as it aims to mitigate future generic competition for its key drug, Cabometyx, by expanding its pipeline. The success of zanzalintinib and other emerging therapies is crucial for the company's long-term oncology focus and investment narrative.
2 Stocks That Could Soar This Year
Exelixis and Summit Therapeutics are highlighted as two biotech stocks with significant growth potential in the coming year. Exelixis is diversifying its oncology pipeline with zanzalintinib ahead of generic competition for Cabometyx, while Summit Therapeutics is advancing its leading candidate ivonescimab, which has shown promise against non-small cell lung cancer and is undergoing multiple phase 3 trials. Both companies have upcoming clinical milestones and FDA submissions that could drive substantial share price appreciation.
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
Exelixis, Inc. announced it will release its fourth quarter and fiscal year 2025 financial results on Tuesday, February 10, 2026, after the market closes. Following the release, Exelixis management will host a conference call and webcast at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a business update. Access to the event will be available through the company's website, with registration required for the conference call.
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
Exelixis (Nasdaq: EXEL) announced it will release its fourth quarter and fiscal year 2025 financial results on Tuesday, February 10, 2026, after market close. Management will then host a conference call and webcast at 5:00 p.m. ET (2:00 p.m. PT) to discuss the results and provide a business update. Access to the event will be available through registration for the conference call or via a live webcast on the company’s website.
Exelixis and Summit Therapeutics: Future Prospects
Exelixis is advancing its next-generation cancer drug zanzalintinib, with an FDA application pending and new phase 3 trials planned, as it aims to replace its現有的 drug Cabometyx before its patent expires in 2030. Meanwhile, Summit Therapeutics' ivonescimab shows significant potential, having outperformed Keytruda in studies, and could achieve substantial market share and peak sales of $53 billion if it secures FDA approval. Analysts project a positive outlook for Exelixis, with an average 1-year price target of $44.09 for EXEL stock.
Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026
Exelixis, Inc. announced it will release its fourth quarter and fiscal year 2025 financial results on Tuesday, February 10, 2026, after market close. A conference call and webcast will follow at 5:00 p.m. ET / 2:00 p.m. PT to discuss the results and provide a business update. Information on how to register for the call and access the webcast is available on the company’s website.
Exelixis Inc (NASDAQ:EXEL) Emerges as a Compelling Value Investment Opportunity
Exelixis Inc (NASDAQ:EXEL) is identified as a compelling value investment opportunity, showing strong financial health and growth prospects. The company received a high basic rating of 8 out of 10, with notable scores in valuation, financial condition, quality of earnings, and growth. Its low valuation ratios, debt-free balance sheet, high profit margins, and projected earnings growth make it an attractive prospect for value investors seeking underpriced quality.
Exelixis Charts Clinical Course for 2026 with Key Partnerships and Buyback
Exelixis has outlined its clinical and financial strategy for 2026, focusing on a new Phase 3 collaboration with Natera Inc. for colorectal cancer and the potential regulatory approval of its investigational therapy, zanzalintinib. The company initiated a $750 million share repurchase program and projected 2026 revenues between $2.525 billion and $2.625 billion, while analysts hold mixed views on its stock due to competitive pressures and patent risks. Clinical data for zanzalintinib is expected to be a major catalyst.
